相关实验视频

Updated: Jul 17, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

通过生物信息学分析,ELOVL6与肺腺癌的免疫抑制有关

Binyu Chen¹, Kaiyu Shen, Tiantian Zhang

¹The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.

|September 8, 2023

概括

肺腺癌 (LUAD) 中ELOVL6基因表达与临床特征和患者存活率相关. 这一发现突出了ELOVL6作为LUAD潜在的预后标志物和治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

肺腺癌 (LUAD) 是癌症相关死亡的主要原因.
了解推动LUAD进展的分子机制对于开发有效疗法至关重要.

研究的目的:

调查ELOVL6基因表达及其在LUAD中的临床意义之间的相关性.
分析ELOVL6表达,免疫细胞透和LUAD患者预后之间的关系.

主要方法:

利用癌症基因组图谱 (TCGA) 数据库对LUAD组织与正常肺组织中的ELOVL6mRNA表达分析.
使用TIMER,TISDIB和GEPIA2数据库来评估ELOVL6表达与瘤免疫细胞透的相关性.
进行了基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 对ELOVL6相关的共同表达基因的丰富分析.
使用Cell Miner数据库选受ELOVL6表达影响的药物.

主要成果:

在LUAD组织和正常肺组织之间,ELOVL6mRNA表达有显著的差异.
ELOVL6表达与LUAD的各种临床病理特征有很强的相关性.
ELOVL6表达水平与LUAD瘤内特定免疫细胞的透有关.
丰富分析确定了关键的信号通路,并构建了与ELOVL6.6相关的蛋白相互作用网络.
确定了受ELOVL6表达影响的潜在治疗药物.

结论:

ELOVL6在LUAD的发病过程中发挥着重要作用.
ELOVL6表达水平与LUAD临床病理学特征和患者生存预后密切相关.
ELOVL6具有作为预后生物标志物和肺腺癌治疗点的潜力.

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...